It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (CRSP 1.46%) earned approval for its first therapy late last year. The treatment in question is called Casgevy and targets sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), two blood-related diseases. This regulatory development was a significant milestone for CRISPR, but the biotech will need more clinical and regulatory success in the years ahead to keep investors happy.Can CRISPR ...

With CRISPR Therapeutics (CRSP 5.28%) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly. Between the fruits of its ongoing commercialization process and a quickly expanding development pipeline, it's certainly true that it has more than one opportunity at impressing the market and enriching its shareholders.Still, even the most successful companies experience setbacks from time to time, and this biotec ...

Editas Medicine (EDIT -0.98%) and CRISPR Therapeutics (CRSP 1.66%) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that their acumen with gene editing will enable them to make therapies that were impossible to conceive of just a few years ago, and they're both aiming for the same disease markets.But as you may have heard, with the recent launch of its first gene therapy, called Casgevy, CRISPR Therapeutics is now a revenue-stage biote ...

Many stocks that have delivered big gains eventually succumb to the investing equivalent of gravity. However, not all of them do. Some keep the momentum going and going.Three Motley Fool contributors think that they've found high-flying stocks that can go much higher in 2024. Here's why they picked CRISPR Therapeutics (CRSP 1.66%), Eli Lilly (LLY 0.84%), and Novo Nordisk (NVO -0.55%).This biotech still has room to run higherDavid Jagielski (CRISPR Therapeutics): One stock that I don't expect to slow down th ...

In the tech space, certain tech stocks stand as front-liners of innovation and strategic brilliance. This article delves into the riveting strategies of three companies that have not merely weathered the storms of their respective industries, but have charted unprecedented courses of triumph. Read more to explore the first one’s Rule of 60: adherence signifies balance, the second one’s regulatory prowess reshapes therapeutic norms and the third one’s revenue dynamics redefine adaptability. Their strategies ...

ToplineThe Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusion-dependent beta thalassemia—marking the second major U.S. regulatory approval for the emerging gene-editing technology.FILE - This microscope photo provided on Oct. 25, 2023, by the Centers for Disease Control and ... [+] Prevention shows crescent-shaped red blood cells from a sickle cell disease patien ...

- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfu ...

Shares of CRISPR Therapeutics (CRSP -0.91%) climbed 54% in 2023, according to data provided by S&P Global Market Intelligence. The biotech company is developing a number of promising gene-therapy treatments for serious illnesses, but it doesn't currently have any products for sale on the market.CRISPR Therapeutics passed multiple important milestones last year, and the stock moved higher when that news was released. The company is navigating the tricky and expensive regulatory-approval process for its first ...

CRISPR Therapeutics (CRSP -0.91%) has put itself on the map of the healthcare industry as a serious player in gene editing. Now that it has an approved treatment in Casgevy, there's undoubtedly going to be more of a spotlight on the company.Gene-therapy treatments are growing in popularity, and for a larger healthcare company that is perhaps looking into getting into the business, it could be more attractive to simply buy CRISPR Therapeutics than to develop its own therapies.Here's why CRISPR could be an at ...

Cathie Wood has become a top investor, thanks to her investments in innovation. Wood identifies companies developing cutting-edge technologies with game-changing potential and gets in on them early. This way, her funds can benefit as these products or services take the world by storm. This helped the superstar investor's flagship fund, Ark Innovation ETF, soar 67% last year.Wood invests across various industries -- but you can find many of her favorite companies in the area of healthcare. From gene editing ...